Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant

Inclusion Criteria: * Group 1: 55-65 yo patients suffering from Acute Myeloblastic and Lymphoblastic Leukemia, Myelo-displasia, Chronic Myeloid Leukemia and Idiopathic Myelofibrosis (according to IBMDR operative manual) * Group 2: patients \<= 65 yo suffering from lympho-proliferative diseases according the REAL classification: * High-doses chemotherapy relapsed CLL (B and T) * Follicular lymphoma relapsed after 2 standard chemotherapy regimens or after high-doses chemotherapy * Mantellar lymphoma relapsed after 1 standard chemotherapy regimen or after high-doses chemotherapy * Lympho-plasmacytoid and B marginal zone lymphoma in relapse after 2 standard chemotherapy regimens or after high-doses chemotherapy * Advanced (stage ≥ III A) or relapsed T lymphomas * Large B-cells lymphomas in 2nd or further complete remission after relapse from high dose chemotherapy and autotransplant or after 2 standard chemotherapy regimens * Fungal mycosis in advanced stage (≥ III A) or in chemosensitive relapse after 2 lines of chemotherapy and Sezary syndrome in chemosensitive relapse after 1 line of chemotherapy * Hodgkin disease relapse after autotransplant with chemosensitive disease or in relapse after 1 year from chemotherapy and not eligible for autotransplant since an insufficient mobilization of autologous hemopoietic stem cells. Exclusion Criteria: * Performance status \< 70% (Karnofsky) * Left ventricular cardiac ejection fraction \< 40% or receiving treatment for heart failure * …